Search clinical trials for: Crisaborole ointment 2%

Total 16595 results

Pfizer

Completed

A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States, Australia, Canada
Pfizer

Completed

A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis

Healthy | Atopic Dermatitis

Japan
Pfizer

Completed

Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

Japan
Innovaderm Research Inc.

Completed

Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis

Dermatitis, Atopic

Canada
Pfizer

Completed

Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

China, Japan, Korea, Republic of
Pfizer

Completed

Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis

Dermatitis, Atopic

Canada
Pfizer

Completed

Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis

Stasis Dermatitis

United States
Tufts Medical Center
Pfizer

Withdrawn

Topical Crisaborole in Patients With Alopecia Areata

Alopecia Areata

United States
Boston University
Pfizer

Terminated

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis (PAD)

Atopic Dermatitis

United States
University of Colorado, Denver
Pfizer

Active, not recruiting

Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo

Vitiligo

United States
Pfizer

Terminated

A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

Japan
Pfizer

Completed

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

Atopic Dermatitis

China, United States, Turkey, Australia, Canada, Israel
Sun Yat-sen University

Recruiting

Crisaborole Ointment for Skin Toxicity Induced by Cetuximab (COSTIC)

Metastatic Colorectal Cancer | Cetuximab | Skin Toxicity

China
University of California, Irvine
Pfizer

Completed

Characterizing Skin Microbiome Change in Atopic Dermatitis

Atopic Dermatitis | Atopic Dermatitis Eczema

United States
Massachusetts General Hospital
Pfizer

Active, not recruiting

Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Pfizer

Completed

AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

Psoriasis

United States
Pfizer

Completed

Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis

Dermatitis, Atopic

Australia
Johns Hopkins University
Pfizer

Active, not recruiting

Steroid-reducing Effects of Crisaborole

Eczema | Atopic Dermatitis

United States
Pfizer

Completed

Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis

Dermatitis, Atopic

Australia, United States
Clinical Research Center of the Carolinas
Pfizer

Completed

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

Atopic Dermatitis

United States
Northwestern University
Pfizer

Completed

Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

Atopic Dermatitis

United States
Pfizer

Completed

Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis

Dermatitis, Atopic

United States
Technoderma Medicines Inc.
Therapeutics, Inc.

Recruiting

Study of TDM-180935 in Atopic Dermatitis Patients

Atopic Dermatitis

United States
University of Rochester

Completed

ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis

Atopic Dermatitis

United States
Pfizer

Completed

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Dermatitis, Atopic

United States
Pfizer

Completed

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

Dermatitis, Atopic

United States
Duke University
Pfizer

Completed

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

Morphea

United States
Pfizer

Terminated

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

Atopic Dermatitis

United States, Poland, Germany, United Kingdom, Italy, Sweden, Switzerland
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield

Completed

Skin bioMARkers for Atopic Eczema Therapy Evaluation (SMART)

Atopic Eczema/Dermatitis (Non-Specific)

United Kingdom
Ann & Robert H Lurie Children's Hospital of Chicago
Pfizer

Completed

Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

Eczema | Atopic Dermatitis

United States
University of Alabama at Birmingham

Completed

A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis

Seborrheic Dermatitis

United States
Pfizer

Completed

CP-690-550 Ointment For Chronic Plaque Psoriasis

Psoriasis

United States, Canada
US Department of Veterans Affairs
University of Michigan; Saint Joseph Mercy Health System

Completed

Preventing Staphylococcal (Staph) Infection

Staphylococcal Infections

United States
Emory University
Georgia Center for Oncology Research & Education

Not yet recruiting

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

Human Immunodeficiency Virus | Human Papilloma Virus | Anal Intraepithelial Neoplasia | High-Grade Squamous Intraepithelial Lesions

United States
Yin-ku Lin

Completed

Comparison of Refined and Crude Indigo Naturalis Ointment in Treating Psoriasis

Psoriasis Vulgaris

Taiwan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects

Atopic Dermatitis

Japan
Pfizer

Completed

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Plaque Psoriasis | Atopic Dermatitis

United States, Canada, United Kingdom, Japan
Serentis Ltd.

Completed

Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis

Atopic Dermatitis

Germany, Bulgaria, Finland
University of Oklahoma

Not yet recruiting

CBD Effects on Forehead Split Scar Healing

Forehead; Wound
GlaxoSmithKline

Completed

A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis

Psoriasis

Germany
Pfizer

Completed

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis (EMPORIA)

Plaque Psoriasis | Atopic Dermatitis

United States, Australia, Canada, Poland
Dermavant Sciences GmbH

Completed

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis

Atopic Dermatitis

Canada, United States
Changchun GeneScience Pharmaceutical Co., Ltd.

Recruiting

A Study for the Treatment of Dry Eye in Postmenopausal Women

Postmenopausal Women With DED

China
PharmaEssentia
PharmaEssentia Japan K.K.

Completed

Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male Subjects

Healthy Volunteer

Japan
Dermavant Sciences GmbH

Completed

Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

Atopic Dermatitis

United States, Canada
UNION therapeutics

Completed

Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD

Atopic Dermatitis

Bulgaria, Denmark, Poland
Pfizer

Completed

Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis

Psoriasis

Mexico
Reistone Biopharma Company Limited

Active, not recruiting

Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis (MARBLE-23)

Atopic Dermatitis

China
LEO Pharma

Completed

Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema

Hand Eczema

Germany
Pfizer

Completed

Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis

Psoriasis

Mexico

3

Subscribe